AgeneBio Finishes Enrollment for Alzheimer’s Symptoms Trial
AgeneBio has completed enrollment for its phase 2b trial of AGB101 as a treatment for the cognitive impairment caused by Alzheimer’s disease.
AGB101 is a low-dose preparation of levetiracetam, an anti-convulsant medication originally developed for the treatment of epilepsy.
The 78-week study has enrolled 164 patients at 23 clinics in the U.S. and Canada to assess AGB101’s cognitive and functional efficacy, the company said. AGB101 works by reducing overactivity in the hippocampus and improving episodic memory.
“The scale of interest that we've seen in this trial … underlines the urgency of unmet needs in Alzheimer's research,” said Sharon Rosenzweig-Lipson, AgeneBio’s vice president of research and development.